SCHEMBL5537784

SCHEMBL5537784

CC(C)Oc1cccc(CN[C]=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.44
MEF2D Q14814 1/20 0.44
FFAR1 O14842 3/20 0.43
P2RX3 P56373 1/20 0.43
ROCK2 O75116 1/20 0.43
ROCK1 Q13464 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
ACACB O00763 1/20 0.42
DHFR P00374 1/20 0.42
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 2/20 0.42
NSD2 O96028 1/20 0.42
ACHE P22303 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3305886 0.82 CHRM2 (0.55) MEN1KMT2ALMNAALDH1A1SMN1; SMN2
SCHEMBL255100 0.80 DHFR (0.49) HDAC4MEF2DFFAR1P2RX3ROCK2
SCHEMBL5547196 0.80 POLB (0.50) MEN1KMT2ALMNANPC1RAB9A
SCHEMBL5548182 0.79 SMN1; SMN2 (0.53) HDAC4MEF2DROCK2ROCK1KMT2A
SCHEMBL9781777 0.79 P2RX3 (0.46) P2RX3MEN1KMT2AACACBDHFR
SCHEMBL2938384 0.78 NPC1 (0.56) HDAC4MEF2DFFAR1ROCK2ROCK1
SCHEMBL5537789 0.78 ADH1B (0.49) HDAC4MEF2DFFAR1P2RX3ROCK2
SCHEMBL3305901 0.77 ALDH1A1 (0.54) MEN1KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL8053740 0.76 P2RX3 (0.49) P2RX3MEN1KMT2ANPC1RAB9A
SCHEMBL17788596 0.76 DHFR (0.49) HDAC4MEF2DFFAR1P2RX3ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HDAC4 707/4885MEF2D 2039/4885FFAR1 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.